press center press release

AVEO Pharmaceuticals, Inc. (AVEO) President and CEO to Ring the NASDAQ Stock Market Closing Bell

Published

ADVISORY, June 21, 2010 (GLOBE NEWSWIRE) --

What:

Tuan Ha-Ngoc, president and chief executive officer of AVEO, will preside over the Closing Bell. Members of the AVEO executive leadership team, AVEO co-founders and Anthony Evnin, Ph.D., chairman of the Board of Directors, will join Mr. Ha-Ngoc.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Tuesday, June 22, 2010 at 3:50 p.m. to 4:00 p.m. ET    

Contact:

Caton Lovett, Pure Communications

(910) 232-7166

NASDAQ MarketSite:

Jolene Libretto 

(646) 441-5220

Jolene.Libretto@NASDAQOMX.com

Feed Information:

The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.

Radio Feed:

An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/pages/NASDAQ-OMX/108167527653

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaqomx

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at:

http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a high-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About AVEO Pharmaceuticals, Inc. (AVEO):

AVEO Pharmaceuticals (Nasdaq:AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with potential for a best-in-class profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development that both increases the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries.  NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).

NDAQA

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more